NHS Kingston
Home > 9 Nutrition and blood > 9.1 Anaemias and some other blood disorders > 9.1.6 Drugs used in neutropenia

9.1.6 Drugs used in neutropenia



Injection 30million units/0.5ml-Biosimilar pre-filled syringes

PbR Excl


Injection 263 micrograms = 33.6million units/vial PbR Excl

MHRA Drug Safety Update Sep 2013: Filgrastim and pegfilgrastim: risk of capillary leak syndrome. Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Prescribers should monitor patients and healthy donors for signs and symptoms of capillary leak syndrome (CLS), and should give standard symptomatic treatment immediately if symptoms occur

Site by Devopa
© Copyright 2022 NHS. All rights reserved.